ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pandemic flu H5 HA mRNA SD2 vaccine

Its studies are mostly in Influenza, Human, led by Sanofi.

Furthest: phase 2, since Mar 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Mar 26, 2025Mar 26, 2025Dec 1, 2026phase 2 · NCT06907511

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2025First study: phase 2 study in Pandemic Influenza ImmunizationFirst studyNCT06907511 · 720 enrolled · United States

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Pandemic Influenza ImmunizationNCT06907511

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Pandemic flu H5 HA mRNA SD2 vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06907511Pandemic Influenza Immunization · United States2Active, not recruitingDec 1, 2026720

How it is read

Names in the registry

  • “Pandemic flu H5 HA mRNA SD2 vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.